Navigation Links
After 18 Months On the U.S. Market, Regeneron's Eylea Captures One-Fifth of First-Line Intravitreal Pharmacotherapy Share Among Wet Age-Related Macular Degeneration (AMD) Patients
Date:7/10/2013

EXTON, Pa., July 10, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the majority of wet age-related macular degeneration (AMD) patients are administered their first intravitreal anti-vascular endothelial growth factor (VEGF) agent within the same month of initial wet AMD diagnosis. Roche/Genentech's Avastin has captured nearly half of first-line allocation, making Avastin the most likely therapy choice despite not being approved for wet AMD. The ChartTrends: Wet AMD (US) report finds that, after approximately 18 months on the market, Regeneron's Eylea owns one-fifth of first-line intravitreal pharmacotherapy (IVT) share among wet AMD patients, lagging only slightly behind that of Roche/Genentech's Lucentis (27 percent), which has been commercially available in the United States since 2006. A comparison of actual patient-level data and self-reported perceptions from more than 140 surveyed retinal specialists and general ophthalmologists suggests that, while physicians correctly perceive the presence of retinal and subretinal fluid as a major driver of treatment initiation, they underestimate the role of a loss in visual acuity in their decision to start patients on treatment.

(Logo:  http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The report—an audit of more than 700 patient charts—also finds that, when the need for convenient dosing frequency is a driver for current brand choice, physicians are more likely to treat patients with Eylea than Avastin or Lucentis, in line with Eylea's label for extended dosing frequency and lack of monthly monitoring.

"However, even as physicians rate current Eylea-treated patients as being significantly more compliant than current Avastin-treated patients, the number of office visits patients have attended or missed in the past year did not differ between Avastin, Eylea or Lucentis," said BioTrends Research Group, Senior Business Insights Analyst Emma Williams, Ph.D. "In addition, no differences were observed between the dosing frequency of the anti-VEGF agents in this patient-level audit."

When presented with profiles of products in development for wet AMD and asked to hypothetically choose one product to switch the audit patient to, Allergan's AGN-150998 (anti-VEGF DARPin) and Ophthotech's Fovista are most frequently chosen, owing to their alternative mechanisms of action, AGN-150998's more convenient administration, and the anticipated synergistic effect of Fovista when administered as adjunctive therapy with an anti-VEGF agent. While no difference exists between candidates and noncandidates in terms of their current anti-VEGF therapy, AGN-150998 candidates are significantly more likely to have been started on their current IVT due to expectations of efficacy in slowing vision loss or efficacy in restoring vision, suggesting that surveyed physicians are optimistic that AGN-150998 may provide a superior effect on vision compared to currently available products.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Operating without interrupting warfarin reduces risk of bleeding after cardiac device surgery
2. Street Named After EMCO High Voltage Corporation
3. Cell Therapeutics to Report First Quarter Financial Results after Market on May 2, 2013
4. Pesticide-Exempt Bed Bug Spray Offered to Public After Bed Bugs Troubled a Lincoln Care Facility, My Cleaning Products Relates How to Get One
5. Study: Brain Imaging After Mild Head Injury/Concussion Can Show Lesions
6. Non-Toxic Bed Bug Spray Offers Complimentary Sample to Court After a Man Infected It With Bed Bugs, My Cleaning Products Explains How Others Could Get a Sample
7. New injectable hydrogel encourages regeneration and improves functionality after a heart attack
8. Walking again after spinal injury
9. Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets
10. First Effective Treatment For Traumatic Brain Injury Reported by Institute of Neurological Recovery, Even Years After Injury
11. New wave of technologies possible after ground-breaking analysis tool developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... ... delivering cutting-edge information focused on the development and manufacture of biopharmaceuticals and ... premier sponsor of the 2016 BioProcess International Awards – Recognizing Excellence in ...
(Date:2/11/2016)... 11, 2016   BioInformant announces the February ... Research Products, Opportunities, Tools, and Technologies – Market Size, ... The first and ... cell industry, BioInformant has more than a decade of ... market, by stem cell type. This powerful 175 page ...
(Date:2/11/2016)... ... 11, 2016 , ... Global Stem Cells Group, ... Ecuador. The new facility will provide advanced protocols and state-of-the-art techniques in cellular ... , The new GSCG clinic is headed by four prominent Ecuadorian physicians, ...
(Date:2/10/2016)...  The Maryland House of Delegates and House Speaker ... of Maryland School of Medicine Dean E. Albert ... Medical System President and CEO Robert Chrencik , ... honor given to the public by the leader of ... and Mr. Chrencik for their contributions to our ...
Breaking Biology Technology:
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
(Date:1/27/2016)... , Jan. 27, 2016  Rite Track, Inc. a ... West Chester, Ohio announced today ... service staff, based in Austin, Texas ... ability to provide modifications, installations and technical support offerings ... CEO of PLUS, commented, "PLUS has provided world class ...
(Date:1/22/2016)... http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ... "Global Biometrics Market in Retail Sector 2016-2020" ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced the ... in Retail Sector 2016-2020" report to ... and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has announced ...
Breaking Biology News(10 mins):